NFL Biosciences SA

Paris Stock Exchange ALNFL.PA

NFL Biosciences SA Net Income for the year ending December 31, 2023: USD -4.13 M

NFL Biosciences SA Net Income is USD -4.13 M for the year ending December 31, 2023, a -58.13% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.
  • NFL Biosciences SA Net Income for the year ending December 31, 2022 was USD -2.61 M, a -134.77% change year over year.
  • NFL Biosciences SA Net Income for the year ending December 31, 2021 was USD -1.11 M, a -242.08% change year over year.
  • NFL Biosciences SA Net Income for the year ending December 31, 2020 was USD -325.53 K, a -8.25% change year over year.
  • NFL Biosciences SA Net Income for the year ending December 31, 2019 was USD -300.71 K.
Key data
Date Net Income EPS (Diluted) Shares (Diluted, Weighted) Net Income Margin
Market news
SV Wall Street
Paris Stock Exchange: ALNFL.PA

NFL Biosciences SA

CEO Dr. Ignacio Faus M.B.A., Ph.D.
IPO Date July 5, 2021
Location France
Headquarters 199 Rue Helene Boucher
Employees 4
Sector Consumers Staples
Industries
Tobacco Biotechnology Pharmaceuticals
Description

NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

Similar companies

ABNX.PA

ABIONYX Pharma SA

USD 1.26

-0.99%

StockViz Staff

February 7, 2025

Any question? Send us an email